Latest Sales Growth News

Cochlear Limited has lowered its FY25 earnings guidance due to slower-than-expected sales growth and a sharper decline in Services revenue. Despite this, implant unit growth remains on track, driven by emerging markets.

Clover Corporation has upgraded its FY25 earnings forecast, expecting net profit after tax to exceed market consensus by around 20%, driven by strong sales and operational improvements.

Pure Foods Tasmania has raised $100,000 through a share placement and appointed directors to new operational roles aimed at driving sales growth and improving cost efficiency.

AnteoTech Ltd has completed a strategic review that refocuses its business on commercialising existing products, delivering $1.6 million in annual cost savings and expanding its sales pipeline in battery and life sciences markets.

Hydralyte USA reports its best EBITDA performance since IPO, driven by strong sales and cost reductions, setting the stage for growth with upcoming product launches.

Little Green Pharma Ltd has reported a robust turnaround for FY2025, posting a $3.3 million profit after tax on revenues up 43%, driven by strong growth in Australia and Europe and strategic acquisitions.

HNG has consolidated its position in the school uniform sector by acquiring full ownership of Global Uniform Solutions and announcing a transformative acquisition of Trutex Group, setting the stage for significant growth across key markets.

Eden Innovations Ltd reports a striking 86% year-on-year sales increase for its EdenCrete® Pz7 concrete admixture, driven by expanding installations in the US, Ecuador, Mexico, and Canada. The company’s innovative product is gaining traction for its cost-saving and environmental benefits in the construction sector.

Eden Innovations reports a significant surge in EdenCrete® product sales, led by the rapid adoption of EdenCrete® Pz7 across the US, Ecuador, Mexico, and Canada. Sales for April-May 2025 alone outpaced the previous year’s quarter by 86%, signaling strong market momentum.

Aroa Biosurgery has reported FY25 results that exceed revenue guidance and deliver a positive normalised EBITDA, setting the stage for ambitious growth and reimbursement expansion in FY26.

Aroa Biosurgery has reported a robust 23% revenue increase in FY25, achieving profitability and positive cash flow, setting the stage for continued growth in FY26.

TruScreen Group Ltd reports a dip in FY25 sales but forecasts a robust rebound in FY26 driven by resumed programs and expansion in key emerging markets. Strategic partnerships and AI-enabled technology underpin its growth ambitions.